scholarly journals A meta‐analysis on allergen‐specific immunotherapy using MCT ® (MicroCrystalline Tyrosine)‐adsorbed allergoids in pollen allergic patients suffering from allergic rhinoconjunctivitis

2021 ◽  
Vol 11 (4) ◽  
Author(s):  
Sven Becker ◽  
Petra Zieglmayer ◽  
Gabriela Canto ◽  
Filippo Fassio ◽  
Patrick Yong ◽  
...  
Keyword(s):  
Specific Immunotherapy ◽  
Meta Analysis ◽  
Allergic Rhinoconjunctivitis ◽  
Allergen Specific Immunotherapy

Allergen-specific immunotherapy for respiratory allergies: From meta-analysis to registration and beyond

2011 ◽  
Vol 127 (1) ◽  
pp. 30-38 ◽  
Author(s):  
Moisés A. Calderón ◽  
Thomas B. Casale ◽  
Alkis Togias ◽  
Jean Bousquet ◽  
Stephen R. Durham ◽  
...  
Keyword(s):  
Specific Immunotherapy ◽  
Meta Analysis ◽  
Allergen Specific Immunotherapy ◽  
Respiratory Allergies

scholarly journals A comparison of different methods of the allergen-specific immunotherapy in patients with pollinosis: the results of open randomized study

2019 ◽  
Vol 16 (3) ◽  
pp. 35-45
Author(s):  
A Y Nasunova ◽  
N M Nenasheva
Keyword(s):  
Pollen Season ◽  
Specific Immunotherapy ◽  
Allergic Rhinoconjunctivitis ◽  
Nasal Lavage ◽  
Subcutaneous Immunotherapy ◽  
Immune Reactivity ◽  
Allergen Specific Immunotherapy ◽  
New Findings ◽  
Study Results ◽  
Specific Igg4

Background. Allergen-specific immunotherapy (ASIT) is viewed as the only treatment that influences all patho-genetically significant parts of the allergic process in the initial and late phases of the IgE-mediated allergic reaction and modifies the abnormal immune reactivity to a specific allergen. Currently, sublingual (SLIT) and subcutaneous (SCIT) immunotherapy are most commonly used in clinical practice. Despite long experience of sublingual and subcutaneous immunotherapy application, questions remain about the preferred ASIT method and comparative effectiveness of different ASIT methods. This article evaluates the efficacy, benefits of SCIT and SLIT and highlights new findings related mechanisms and potential biomarkers. The aim of the study. To evaluate the comparative efficacy of different methods of ASIT (subcutaneous and sublingual) based on clinical data and biomarkers in the blood serum and other biological fluids in adult patients with allergic rhinoconjunctivitis (with/without asthma). Materials and methods. 60 patients with allergic rhinoconjunctivitis (with/without asthma) aged 18 to 50 were randomly assigned to 3 groups treated by sublingual immunotherapy with extracts of allergens, subcutaneous immunotherapy with extracts of allergens and subcutaneous with modified allergens (allergoids) respectively. Results. The efficiency of the first course of preseason ASIT (SCIT and SLIT) with extracts of allergens and aller-goids in the control of symptoms of allergic rhinoconjunctivitis (with/without asthma) was demonstrated. After the end of the first year pre-season ASIT data analysis scales (Total Symptom Score -TSS, Medircation Score -MS) revealed the best performance in the group of patients receiving SCIT with allergoids compared with patients receiving the SLIT with extracts of allergens: the scales of the TSS (p=0.023), MS (p=0.002). In addition, at the end of the maintenance phase of ASIT in patients treated with SCIT with allergoids the level of eosinophilic cationic protein (ECP) in the nasal lavage decreased by 22% (p=0.012), secretory immunoglobulin A (sIgA) in the nasal lavage increased by 70% (p=0.001), interleukin-10 (IL-10) in serum increased by 126% (p=0.006), allergen-specific IgG4 increased by 42% (p=0.01) from the initial values, that correlates with a decrease in the severity of clinical manifestations. In pollen season ECP level in nasal lavage was significantly (p=0.007) lower in a group of patients who received SCIT with allergoids compared with patients who received the SLIT with extracts of allergens. The most significant changes of serum level of IL-10 in the pollen season occurred in a group of patients receiving SCIT with allergoids compared with patients who received SLIT (p=0.013) and SCIT (p=0.001) with extracts of allergens. Conclusion. The study results deepen the existing understanding of the mechanisms of SCIT and SLIT. They allow to develop a comprehensive assessment of the therapy efficacy scheme based on clinical parameters and on monitoring of local (ECP, sIgA) and systemic biomarkers (IL-10, allergen-specific IgG4) as well.

scholarly journals Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis

2012 ◽  
Vol 18 (10) ◽  
pp. CR617-CR621 ◽  
Author(s):  
Arzu Didem Yalcin ◽  
Saadet Gumuslu ◽  
Gizem Esra Parlak ◽  
Atil Bısgın
Keyword(s):  
Specific Immunotherapy ◽  
Allergic Rhinoconjunctivitis ◽  
Allergen Specific Immunotherapy ◽  
Soluble Trail

scholarly journals Current issues on sublingual allergen-specific immunotherapy in children with asthma and allergic rhinitis

2016 ◽  
Vol 144 (5-6) ◽  
pp. 345-350 ◽  
Author(s):  
Zorica Zivkovic ◽  
Ivana Djuric-Filipovic ◽  
Snezana Zivanovic
Keyword(s):  
Allergic Rhinitis ◽  
Clinical Efficacy ◽  
Randomized Clinical Trials ◽  
Specific Immunotherapy ◽  
Meta Analysis ◽  
Immune Therapy ◽  
Real Life ◽  
World Health ◽  
Sublingual Administration ◽  
Allergen Specific Immunotherapy

In 1993 the European Academy of Allergy and Clinical Immunology was the first official organization to recognize that sublingual administration could be ?promising route? for allergic desensitization. A few years later, the World Health Organization recommended this therapy as ?a viable alternative to the injection route in adults.? The first meta-analysis showed sublingual allergen specific immunotherapy (SLIT) effectiveness for allergic rhinitis and another study showed SLIT can actually help prevent the development of asthma both in adults and in children. The main goal of this review article is to present insight into the most up-to-date understanding of the clinical efficacy and safety of immunotherapy in the treatment of pediatric patients with allergic rhinitis and asthma. A literature review was performed on PubMed from 1990 to 2015 using the terms ?asthma,? ?allergic rhinitis,? ?children,? ?allergen specific immune therapy.? Evaluating data from double-blind placebo-controlled randomized clinical trials (DB-PC-RCTs), the clinical efficacy (assessed as the reduction of symptom score and the need of rescue medicament) of SLIT for allergic rhinitis and allergic asthma, has been confirmed in various meta-analysis Outcomes such as rhinoconjunctivitis score and medication scores, combined scores, quality of life, days with severe symptoms, immunological endpoints, and safety parameters were all improved in the SLIT-tablet compared with placebo group. SLIT safety has been already proven in many DB-PC-RCTs and real-life settings. In accordance with all of the above mentioned, the goals for future trials and studies are the development of comprehensive guidelines for clinical practice on immunotherapy, embracing all the different potential participants. The importance of allergen immunotherapy is of special relevance in the pediatric age, when the plasticity and modulability of the immune system are maximal, and when preventative effects can be reasonably expected.

Sign in / Sign up

Export Citation Format

Share Document